Cargando…

Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany

AIMS: Treatment of iron deficiency (ID) in patients with heart failure (HF) with intravenous iron substitution [ferric carboxymaltose (FCM)] has previously shown significant improvements in exercise capacity, New York Heart Association (NYHA) functional class, quality of life, and reduction of hospi...

Descripción completa

Detalles Bibliográficos
Autores principales: Theidel, Ulrike, Väätäinen, Saku, Martikainen, Janne, Soini, Erkki, Hardt, Thomas, Doehner, Wolfram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542731/
https://www.ncbi.nlm.nih.gov/pubmed/28772041
http://dx.doi.org/10.1002/ehf2.12179
_version_ 1783255047193231360
author Theidel, Ulrike
Väätäinen, Saku
Martikainen, Janne
Soini, Erkki
Hardt, Thomas
Doehner, Wolfram
author_facet Theidel, Ulrike
Väätäinen, Saku
Martikainen, Janne
Soini, Erkki
Hardt, Thomas
Doehner, Wolfram
author_sort Theidel, Ulrike
collection PubMed
description AIMS: Treatment of iron deficiency (ID) in patients with heart failure (HF) with intravenous iron substitution [ferric carboxymaltose (FCM)] has previously shown significant improvements in exercise capacity, New York Heart Association (NYHA) functional class, quality of life, and reduction of hospitalization. The aim of this study was to estimate the budget impact of FCM treatment for patients with HF and ID. METHODS AND RESULTS: Individual patient data from four double‐blind randomized controlled trials were pooled for this analysis. Expected outcomes were modelled for a treatment period of 1 year, using multivariate statistical methods. Associated unit costs were derived from claims data. Budget impact was calculated from the perspective of the Statutory Health Insurance. Multiple deterministic sensitivity analyses were performed. The annual budget impact for therapy with FCM vs. no‐iron therapy was €2 735 505 and €2 695 474 for 1000 patients, respectively, resulting in additional annual costs of €40.03 for each treated patient. Main costs drivers are the FCM treatment cost and cost of hospitalizations due to HF worsening. FCM therapy compared with no‐iron therapy resulted in reduced cost per 1000 patients: for reduced hospitalization due to HF worsening (52 vs. 129 hospitalizations amounting to €230 591 vs. €597 078), for reduced other medication (€1 611 007 vs. €1 679 908), fewer outpatient visits (€332 523 vs. €378 019), and home visits (€29 627 vs. €40 469). Sensitivity analyses showed robustness of the results. CONCLUSIONS: Therapy with FCM has a minimal budget impact of €40 031 per 1000 patients per year. This budget impact translates into reduced and shorter hospitalizations and improved symptomatic status of the patients.
format Online
Article
Text
id pubmed-5542731
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-55427312017-08-17 Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany Theidel, Ulrike Väätäinen, Saku Martikainen, Janne Soini, Erkki Hardt, Thomas Doehner, Wolfram ESC Heart Fail Original Research Articles AIMS: Treatment of iron deficiency (ID) in patients with heart failure (HF) with intravenous iron substitution [ferric carboxymaltose (FCM)] has previously shown significant improvements in exercise capacity, New York Heart Association (NYHA) functional class, quality of life, and reduction of hospitalization. The aim of this study was to estimate the budget impact of FCM treatment for patients with HF and ID. METHODS AND RESULTS: Individual patient data from four double‐blind randomized controlled trials were pooled for this analysis. Expected outcomes were modelled for a treatment period of 1 year, using multivariate statistical methods. Associated unit costs were derived from claims data. Budget impact was calculated from the perspective of the Statutory Health Insurance. Multiple deterministic sensitivity analyses were performed. The annual budget impact for therapy with FCM vs. no‐iron therapy was €2 735 505 and €2 695 474 for 1000 patients, respectively, resulting in additional annual costs of €40.03 for each treated patient. Main costs drivers are the FCM treatment cost and cost of hospitalizations due to HF worsening. FCM therapy compared with no‐iron therapy resulted in reduced cost per 1000 patients: for reduced hospitalization due to HF worsening (52 vs. 129 hospitalizations amounting to €230 591 vs. €597 078), for reduced other medication (€1 611 007 vs. €1 679 908), fewer outpatient visits (€332 523 vs. €378 019), and home visits (€29 627 vs. €40 469). Sensitivity analyses showed robustness of the results. CONCLUSIONS: Therapy with FCM has a minimal budget impact of €40 031 per 1000 patients per year. This budget impact translates into reduced and shorter hospitalizations and improved symptomatic status of the patients. John Wiley and Sons Inc. 2017-07-03 /pmc/articles/PMC5542731/ /pubmed/28772041 http://dx.doi.org/10.1002/ehf2.12179 Text en © 2017 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research Articles
Theidel, Ulrike
Väätäinen, Saku
Martikainen, Janne
Soini, Erkki
Hardt, Thomas
Doehner, Wolfram
Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany
title Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany
title_full Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany
title_fullStr Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany
title_full_unstemmed Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany
title_short Budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in Germany
title_sort budget impact of intravenous iron therapy with ferric carboxymaltose in patients with chronic heart failure and iron deficiency in germany
topic Original Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5542731/
https://www.ncbi.nlm.nih.gov/pubmed/28772041
http://dx.doi.org/10.1002/ehf2.12179
work_keys_str_mv AT theidelulrike budgetimpactofintravenousirontherapywithferriccarboxymaltoseinpatientswithchronicheartfailureandirondeficiencyingermany
AT vaatainensaku budgetimpactofintravenousirontherapywithferriccarboxymaltoseinpatientswithchronicheartfailureandirondeficiencyingermany
AT martikainenjanne budgetimpactofintravenousirontherapywithferriccarboxymaltoseinpatientswithchronicheartfailureandirondeficiencyingermany
AT soinierkki budgetimpactofintravenousirontherapywithferriccarboxymaltoseinpatientswithchronicheartfailureandirondeficiencyingermany
AT hardtthomas budgetimpactofintravenousirontherapywithferriccarboxymaltoseinpatientswithchronicheartfailureandirondeficiencyingermany
AT doehnerwolfram budgetimpactofintravenousirontherapywithferriccarboxymaltoseinpatientswithchronicheartfailureandirondeficiencyingermany